

S4 Table. Primary, Secondary, and Safety Outcomes

Trial	Primary outcome	Secondary outcomes	Safety outcomes
ORCHID	COVID Ordinal Outcomes Scale on Study Day 15	<ul style="list-style-type: none"> • Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge • All-location, all-cause 14-day mortality (assessed on Study Day 15) • All-location, all-cause 28-day mortality (assessed on Study Day 29) • COVID Ordinal Outcomes Scale on Study Day 3 • COVID Ordinal Outcomes Scale on Study Day 8 • COVID Ordinal Outcomes Scale on Study Day 29 • Composite of death or receipt of ECMO through Day 28 • Oxygen-free days through Day 28 • Ventilator-free days through Day 28 • Vasopressor-free days through Day 28 • ICU-free days through Day 28 • Hospital-free days through Day 28 	<ul style="list-style-type: none"> • Seizure • Atrial or ventricular arrhythmia • Cardiac arrest • Elevation in aspartate, aminotransferase, or alanine aminotransferase to twice the local upper limit of normal • Acute pancreatitis • Acute kidney injury • Receipt of renal replacement therapy
WU352	Time (hours) from randomization to recovery defined as (1) absence of fever, as defined as at least 48 hours since last temperature $\geq 38.0^{\circ}\text{C}$ without the use of fever-reducing medications AND (2) absence of symptoms of greater than mild severity for 24 hours AND (3) not requiring supplemental oxygen beyond pre-COVID baseline AND (4) freedom from mechanical ventilation or death	<ul style="list-style-type: none"> • Time to resolution of fever defined as at least 48 hours since last temperature $\geq 38.0^{\circ}\text{C}$ without the use of fever-reducing medications • Time to improvement in symptoms (scored as mild or absent and remained so for 24 hour) • Mean improvement in symptom from baseline • Duration of hospitalization • Proportion requiring supplementary oxygen (above baseline usage) at any time during follow-up • Duration (days) of requirement for supplementary oxygen • Proportion requiring ICU admission at any time during follow-up • Proportion requiring mechanical ventilation at any time during follow-up • Ventilator free days • All-cause mortality 	<ul style="list-style-type: none"> • Serious Adverse Events that occur within 6 weeks after randomization • Unanticipated problem (UP) • Unexpected adverse drug event (UADE)
NCT04335552 (Duke)	WHO ordinal scale measured at 14 days after enrollment	<ul style="list-style-type: none"> • Death during the index hospitalization • Number of days on mechanical ventilation • Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation 	<ul style="list-style-type: none"> • Arrhythmias (ventricular) • Hepatic failure • Bone marrow failure • Aplastic anemia

Trial	Primary outcome	Secondary outcomes	Safety outcomes
		during the index hospitalization <ul style="list-style-type: none"> • WHO ordinal scale measured at 28 days after enrollment • Hospital length of stay in days for the index hospitalization • Days of fever (temperature ≥ 38.0) after randomization • Days on supplemental oxygen after randomization • All-cause study medication discontinuation • Drug-associated adverse events of special interest 	<ul style="list-style-type: none"> • Prolonged QT interval • Angioedema • Exfoliative dermatitis • Acute generalized exanthematous pustulosis (AGEP) • Psychosis • Suicidal ideation • Seizure • SAEs that occur between initial dose of study medication and day 14
TEACH	A severe disease progression composite endpoint defined by the occurrence of any of the following: mortality, ICU admission, invasive mechanical ventilation, ECMO, and/or hypotension requiring vasopressor support by the 14-day post-treatment evaluation	<ul style="list-style-type: none"> • Composite outcome (mortality, ICU admission, invasive mechanical ventilation, ECMO, and/or hypotension requiring vasopressor support) at 30 days • Individual components of the composite endpoint (mortality, ICU admission, invasive mechanical ventilation, ECMO, and/or hypotension requiring vasopressor support) by EOT, PTE, and 30 days of treatment • Hospital length of stay • Days of fever • Days of non-invasive ventilator use • Days of non-rebreather mask oxygen supplementation • Cytokine release syndrome grading scale • Percentage of subjects reporting each severity score on 8-point ordinal scale D1 and EOT • Percentage of subjects with QTc prolongation at EOT • SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT, measured by RT-PCR • Change from baseline AST, ALT, creatinine, glucose, white blood cell count, lymphocyte percentage, hemoglobin, platelets, total bilirubin, LDH, CRP, and IL-6 at EOT 	<ul style="list-style-type: none"> • Primary Safety Composite: Cumulative incidence of SAEs through day 30, grade 3 or 4 AEs through day 30, and/or discontinuation of therapy (for any reason)
COVID MED	NIAID COVID-19 Ordinal Severity Score	<ul style="list-style-type: none"> • Mortality • Hospital/ICU/ventilator length of stay (LOS) • Reason for ventilator discontinuation (if applicable) • Antibiotics use • Symptoms-based COVID-19 severity score 	<ul style="list-style-type: none"> • Complications • AEs/SAEs
HAHPS	WHO COVID Ordinal Outcomes Scale at 14 days	<ul style="list-style-type: none"> • Hospital-free days at 28 days (calculated as a worst-rank ordinal) • Ventilator-free days at 28 days (calculated as a worst-rank ordinal) 	<ul style="list-style-type: none"> • Counts (proportions) of adverse events • Those listed in the package insert for hydroxychloroquine and azithromycin • QT interval

Trial	Primary outcome	Secondary outcomes	Safety outcomes
		<ul style="list-style-type: none"> • ICU-free days at 28 days (calculated as a worst-rank ordinal) • Time to a 1-point decrease in the WHO ordinal recovery score 	<ul style="list-style-type: none"> • Arrhythmia
NCT04344444 (University Medical Center New Orleans)	Composite incidence of death, transfer to ICU, initiation of mechanical ventilation, or initiation of ECMO	<ul style="list-style-type: none"> • Toxicities of the drugs • SARS-CoV2 viral load over time • Length of hospital stay • Number of ICU days • Rate of readmission after hospital discharge • Duration of symptoms 	<ul style="list-style-type: none"> • AEs monitored daily, including drug toxicity. • QTc monitoring via telemetry
OAHU-COVID19	Clinical status (on a 7-point ordinal scale) at day 15	<ul style="list-style-type: none"> • Time to an improvement of one category from admission using an ordinal scale • Subject clinical status using ordinal scale at days 3, 5, 8, 11, and 28 • Mean change in the ordinal scale from baseline to days 3, 5, 8, 11, 15, and 28 from baseline • The time to discharge or to a National Early Warning Score (NEWS) of ≤ 2 and maintained for 24 hours, whichever occurs first • Oxygenation free days in the first 28 days • Incidence and duration of new oxygen use during the study • Ventilator-free days in the first 28 days • Incidence and duration of new mechanical ventilation use during hospitalization • Duration of hospitalization (days) 	<ul style="list-style-type: none"> • 28-day mortality • Cumulative incidence of serious adverse events (SAEs) through 28-day follow-up • Cumulative incidence of Grade 3 and 4 adverse events • Discontinuation of hydroxychloroquine for any reason • Changes in WBC, Hb, Plt, Creat, CrCl, Gluc, Tot Bili, ALT, AST over time